Cargando…

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?

SIMPLE SUMMARY: Recent studies concerning immunotherapeutic agents are bound to revolutionize therapeutic strategies for esophageal cancer patients. This review aims to summarize novel clinical data and provide a critical view of potential restrictions for the implementation of immunotherapy for uns...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puhr, Hannah Christina, Preusser, Matthias, Ilhan-Mutlu, Aysegül
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472767/ https://www.ncbi.nlm.nih.gov/pubmed/34572859 http://dx.doi.org/10.3390/cancers13184632

Ejemplares similares

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer
por: Puhr, Hannah Christina, et al.
Publicado: (2023)

Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy
por: Puhr, Hannah C., et al.
Publicado: (2022)

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis
por: Puhr, H. C., et al.
Publicado: (2019)

How we treat esophageal squamous cell carcinoma
por: Puhr, H.C., et al.
Publicado: (2023)

PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
por: Beer, Andrea, et al.
Publicado: (2020)

MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2018)

Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity
por: Paireder, Matthias, et al.
Publicado: (2020)

Immunotherapy for Esophageal Cancer: State-of-the Art in 2021
por: Teixeira Farinha, Hugo, et al.
Publicado: (2022)

Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis
por: Puhr, Hannah C., et al.
Publicado: (2021)

Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
por: Puhr, Hannah C., et al.
Publicado: (2023)

NephroCheck data compared to serum creatinine in various clinical settings
por: Pajenda, Sahra, et al.
Publicado: (2015)

Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
por: Puhr, H.C., et al.
Publicado: (2022)

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
por: Jomrich, Gerd, et al.
Publicado: (2018)

Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
por: Fendl, B., et al.
Publicado: (2023)

Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers
por: Barsouk, Adam, et al.
Publicado: (2019)

Immunotherapy for Squamous Esophageal Cancer: A Review
por: Petrillo, Angelica, et al.
Publicado: (2022)

Role of ferroptosis in esophageal cancer and corresponding immunotherapy
por: Fan, Xin, et al.
Publicado: (2023)

Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy
por: Jomrich, Gerd, et al.
Publicado: (2021)

Advances in targeted therapy and immunotherapy for esophageal cancer
por: Yang, Haiou, et al.
Publicado: (2023)

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
por: Vrána, David, et al.
Publicado: (2018)

Molecular biology of high-grade gliomas: what should the clinician know?
por: Hofer, Silvia, et al.
Publicado: (2014)

Metabolic changes during prostate cancer development and progression
por: Beier, Alicia-Marie K., et al.
Publicado: (2022)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
por: Preusser, Matthias
Publicado: (2019)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times
por: Berghoff, Anna Sophie, et al.
Publicado: (2013)

Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer
por: Kadono, Toru, et al.
Publicado: (2022)

Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers
por: Zhang, Xiaoli, et al.
Publicado: (2020)

Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
por: Kole, Christo, et al.
Publicado: (2020)

What Is Recent in Pancreatic Cancer Immunotherapy?
por: Niccolai, Elena, et al.
Publicado: (2013)

Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field
por: Marhold, Maximilian, et al.
Publicado: (2020)

Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012)

Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy
por: Zhang, Yujie, et al.
Publicado: (2019)

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours
por: Mair, Maximilian J, et al.
Publicado: (2020)

Pancreatic cancer in 2021: What you need to know to win
por: Tonini, Valeria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gv70fk83crms9apcqbu9vv2jiu